Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase) [PDF]
Biologics: Targets & Therapy, 2008 Andrea Pession, Fraia Melchionda, Claudia CastelliniOncologia Ematologia Pediatrica “Lalla Seràgnoli”, Clinica Pediatrica, Università degli Studi di Bologna, Bologna, ItalyAbstract: Along with hydration and ...
Andrea Pession +2 more
doaj +7 more sources
Use of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury. [PDF]
Clin Exp Nephrol, 2023 Background Hyperuricemia contributes to decrease in kidney function and induces additional renal damage in children with acute kidney injury (AKI). Rasburicase oxidizes uric acid (UA), decreasing its serum quantities in less than 24 h.
Herrero-Goñi M +5 more
europepmc +6 more sources
The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review [PDF]
Hematology ReportsBackground/Objectives: Rasburicase is licensed for the management of tumor lysis syndrome (TLS) at a daily dose of 0.2 mg/kg intravenously for five days.
Anselm Chi-wai Lee
doaj +2 more sources
Rasburicase in treating tumor lysis syndrome: An umbrella review [PDF]
Cancer Pathogenesis and Therapy, 2023 Tumor lysis syndrome (TLS) remains a debilitating cause of hospitalization and death in patients with cancer and is a significant challenge for healthcare providers despite advancements in its management. This umbrella review analyzed the results of meta-
Kamran Mahfooz +8 more
doaj +2 more sources
South African Journal of Oncology, 2018 Background: Tumour lysis syndrome is a common complication of haematological malignancies and has historically been managed with hyperhydration, urine alkalinisation and allopurinol with renal dialysis reserved for patients in acute renal failure ...
Morné F. Kahts +5 more
doaj +3 more sources
A case report of fatal anaphylaxis on first exposure to rasburicase just before lymphoma treatment [PDF]
Allergy, Asthma & Clinical ImmunologyBackground Rasburicase, a recombinant urate oxidase enzyme, has potent efficacy in controlling uric acid and is widely used to prevent tumor lysis syndrome in high-risk patients owing to its low toxicity profile.
Yoshikazu Utsu +12 more
doaj +2 more sources
In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment [PDF]
Arthritis Research & Therapy, 2023 Background Exogenously providing engineered Uox with enhanced half-life is one of the important urate-lowering treatments for gout. The potential of PAT101, a recombinant human albumin (rHA)-conjugated variant, was evaluated and compared as a novel gout ...
Jeonghaeng Cho +10 more
doaj +2 more sources
Consensus conference on the management of tumor lysis syndrome [PDF]
Haematologica, 2008 Tumor lysis syndrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in the institution of appropriate treatments.
Patrizia Tosi +10 more
doaj +3 more sources
Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐cell lymphoma: Insights from real‐life clinical practice [PDF]
Cancer ReportsBackground Tumor lysis syndrome (TLS) is a potentially life‐threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures.
Jasmine Mohamad +8 more
doaj +2 more sources
Journal of Blood Medicine, 2011 LeAnne D Kennedy1 Susannah Koontz2 Kamakshi Rao31Wake Forest University Baptist Medical Center, Winston Salem, NC, USA; 2Koontz Oncology Consulting LLC, Houston, TX, USA; 3UNC Hospitals, Chapel Hill, NC, USAAbstract: Tumor lysis syndrome (TLS) is defined
LeAnne D Kennedy +2 more
doaj +3 more sources